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Abstract
Background: Methamphetamine (Meth) abuse is a major health problem linked to the aggravation of HIV- associated
complications, especially within the Central Nervous System (CNS). Within the CNS, Meth has the ability to modify the
activity/function of innate immune cells and increase brain viral loads. Here, we examined changes in the gene
expression profile of neuron-free microglial cell preparations isolated from the brain of macaques infected with the
Simian Immunodeficiency Virus (SIV), a model of neuroAIDS, and exposed to Meth. We aimed to identify molecular
patterns triggered by Meth that could explain the detection of higher brain viral loads and the development of a pro-
inflammatory CNS environment in the brain of infected drug abusers.
Results: We found that Meth alone has a strong effect on the transcription of genes associated with immune pathways,
particularly inflammation and chemotaxis. Systems analysis led to a strong correlation between Meth exposure and
enhancement of molecules associated with chemokines and chemokine receptors, especially CXCR4 and CCR5, which
function as co-receptors for viral entry. The increase in CCR5 expression was confirmed in the brain in correlation with
increased brain viral load.
Conclusions: Meth enhances the availability of CCR5-expressing cells for SIV in the brain, in correlation with increased
viral load. This suggests that Meth is an important factor in the susceptibility to the infection and to the aggravated CNS
inflammatory pathology associated with SIV in macaques and HIV in humans.
Keywords: Methamphetamine, NeuroAIDS, Microglia, CCR5, Simian immunodeficiency virus, Human immunodeficiency
virus, Brain, Central nervous system, Inflammation
Background
NeuroAIDS refers to a series of neurological complica-
tions that arise as a result of HIV infection. The effects
of NeuroAIDS cannot be prevented by antiviral drugs
[1] and, importantly, are aggravated by drugs of abuse
such as Methamphetamine (Meth) [2]. Meth is a highly
addictive drug, inducing behaviors that increase the
users’ risk to HIV exposure [3–5]. HIV-positive individ-
uals that make use of Meth, have a higher incidence of
systemic and Central Nervous System (CNS) inflamma-
tory pathology when compared to non-Meth users [2, 6].
Within the CNS, microglia and macrophages are the
cells dedicated to immune defense of the brain. These
cells regulate CNS physiology and inflammation by se-
creting cytokines/growth factors and become reactive to
CNS/systemic insult [7, 8]. In the post-antiretroviral
(ART) era, HIV is mainly a chronic infection, in which
microglia exhibit long-lasting changes in gene expres-
sion. Such changes may not be simply part of an adap-
tive microglial response to the virus, but may also result
in adverse consequences for neurons and/or synapses.
Microglia, which correspond to 10–20 % of the total
* Correspondence: cmarcond@scripps.edu
†Equal contributors
1Cellular and Molecular Neurosciences Department, The Scripps Research
Institute, 10550 North Torrey Pines Rd. SR307, La Jolla, CA 92037, USA
Full list of author information is available at the end of the article
© 2016 Najera et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Najera et al. BMC Immunology  (2016) 17:7 
DOI 10.1186/s12865-016-0145-0
brain cells [9, 10], are major targets of SIV/HIV virus
due to their expression of CCR5 [11]. Identifying
changes in brain-isolated and enriched microglial prepa-
rations allows for the detection of minor signals that po-
tentially influence immune function in the brain. From
these signals we can extrapolate the contribution of the
innate immune system in CNS degeneration within the
context of HIV infection and aggravation by drug abuse.
Several studies have reported that Meth triggers activa-
tion of microglial cells in animal models [12–17]. It has
been also reported that Meth users have signs of microglial
activation, as seen by the accumulation of the microglial ac-
tivation marker (1-(2-chrorophynyl)-N-methylpropyl)-3 iso-
quinoline carboxamide ([11C]PK11195) [18]. Here, using
SIV infected rhesus macaques as a non-human primate
model of neuroAIDS, we found that Meth modulates the
phenotype of brain innate immune cells by increasing
microglial activation and pro-inflammatory cytokine secre-
tion. In addition, Meth also increased CCR5 expression at
the surface of innate immune [19]. As a consequence, viral
load was also elevated in the brain of Meth-treated animals
compared to placebo-treated animals. We further examined
Fig. 1 Characterization of cell subpopulations in the brain-derived cell isolates. Percoll-isolated cells from the brain of rhesus macaques were utilized in this
study. These cells were characterized based on the expression of surface markers of cell subpopulation, and analyzed flow cytometry. a Cell gating strategies.
The cells were gated based on the expression of CD11b (myeloid cell marker) and CD45LCA (peripheral cell marker), where CD11bint CD45LCA- cells are
microglia, CD11b +CD45LCA+ cells are macrophages and CD11b-CD45LCA+ cells are mostly lymphocytes. The identity of microglia and macrophages was
further confirmed by the CD14 and CD16 expression patterns. b Percentage of Lymphoid cells. The CD11b- population was characterized based on
the expression of lymphocyte markers CD3, CD4 and CD8, and the relative differences in the percentage of lymphocyte subsets between groups is
shown. *p≤ 0.05 compared to uninfected controls. c Myeloid cell subset characterization. Myeloid cell subsets were differentially analyzed based on
the expression of inflammatory status surface markers, CX3CR1, CD44v6, CCR5, CCR2 and CD80. *p ≤ 0.05 compared to uninfected controls.
Microglia activation: Immunohistochemical detection of Iba-1 microglial marker in brains from animals that were (d) Controls, (e) SIV-
infected, (f) Meth-treated, (g) SIV-infected and Meth-treated. Sections from the frontal cortex were examined for the frequency and distribution
of Iba-1-expressing cells. The panels show one representative animal per group
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the actions of in vivo administration of Meth on the pheno-
type of microglial cells isolated from the brain of control
and SIV-infected macaques. For that, we examined if Meth
altered the microglial gene expression profile in a way that
could elucidate the enhanced severity of virus-triggered
tissue-pathology that is observed in HIV+ Meth abusers.
Our results demonstrate that Meth alters the pro-
inflammatory phenotype of brain innate immune cells and
this effect is enhanced in the context of SIV infection. Thus,
our data suggests that Meth alters the microglial gene ex-
pression profile in a way that can explain the enhanced se-
verity of virus-triggered tissue pathology in HIV positive
Meth users.
Results and discussion
A. High score pathways and most up-regulated genes in
brain-isolated immune cells
We have profiled changes in gene expression of brain-
derived CD11b-enriched immune cells (Fig. 1a), in
healthy (control n = 5) and SIV-chronically infected ma-
caques, treated (SIV/Meth n = 4) or not with Meth (SIV
only n = 4). Uninfected animals that received Meth were
also included as abuse controls (Meth only n = 4). For
comparison, we also profiled genes from microglia iso-
lated from animals exhibiting encephalitis associated to
disease progression (SIVE n = 4). All infected animals
had equivalent and stable SIV viremia [19], when Meth
treatment was initiated post acutely. This approach
allowed the identification of changes in the microglial
phenotype that were driven by the introduction of drug.
Importantly, and as described previously [19], the intro-
duction of Meth did not affect viral load in the plasma
in comparison to the SIV group.
The characterization of the brain-derived innate im-
mune cells analyzed in this study was performed using
flow cytometry and cell subset surface markers, such as
CD45LCA (which characterizes cells that have a periph-
eral origin), CD11b (which characterizes innate immune
cells) (Fig. 1a left), in addition to other innate immune
cell markers CD14 and CD16, which estimate the in-
flammatory status when plotted together (Fig. 1a right).
In Fig. 1a, a representative sample exemplifies the gating
strategy used in this study, based on the distribution of
CD45LCA and CD11b-positive cells (Fig. 1a left), and
showing the general aspect of brain preparations in flow
cytometry. The majority of the cells in the isolates were
CD11bint/+ CD45LCAlow cells microglia, followed by a
subpopulation of CD11b + CD45LCAhi macrophages
and a CD11bint CD45LCAhi subset (containing <2 %
CD19+ B cells- and <4 % CD11c +myeloid dendritic
cells - not shown). On the other hand, within the gated
CD11bint CD45lo microglia cells, the majority expressed
CD16lo and CD14int levels, but a small population ex-
pressing CD16hi was also identified. The CD11b +
CD45LCAhi macrophages were CD14 hi, but these cells
had a range of CD16 expression levels, from intermedi-
ate to high. For the most part, this cell distribution pat-
tern was maintained throughout the groups.
Within the CD45LCA+ cells, we have also examined
the presence of CD11b-negative cells, expressing CD3 (a
marker of T lymphocytes), together with either CD4 (a
marker of T helper cells) or CD8 (a marker of NK and
cytotoxic T cells) (Fig. 1b). Among these lymphoid sub-
sets, SIV infection induced an enrichment of cytotoxic T
cells (Fig. 1b), as expected. In addition, changes in rela-
tive numbers of CD3 + CD8+ T cells, but not other
lymphoid cells, were due to SIV infection and were not
affected by Meth (Fig. 1b). However, we have previously
shown that Meth does increase the activation of CD3 +
CD8+ cells and CD3-CD8+ NK cells [19].
The CD11b-positive cells expressing CD14 and differ-
ent levels of CD16, were further analyzed according to
inflammatory markers that are relevant in the SIV/HIV
neuropathogenesis, such as the Osteopontin receptor
CD44v6, chemokine receptors CX3CR1, CCR5 and
CCR2, and the activation marker CD80 (Fig. 1c). Al-
though the overall percentages of the most dominating
innate immune cell subsets, such as microglia and mac-
rophages, were not significantly affected by Meth, we
did observe changes in the expression of activation
markers (Fig. 1c). For example, we detected an increase
in levels of chemokine receptors CX3CR1 and CCR5 on
macrophages (Fig. 1c). Interestingly, this effect was de-
tected, particularly, on cells displaying characteristics of
resident microglia, as well as on the macrophage subset
that was CD14-positive but still retained the CD16low
phenotype (Fig. 1c), suggesting the onset of cells with an
intermediate inflammatory phenotype. The activation of
microglia was largely detectable by histopathology and
immunohistochemistry, using the Iba-1 antibody, which
detects the Allograft Inflammatory Factor 1 (AIF1) – a
marker of microglial activation (Fig. 1d-g). For instance,
the histopathological findings suggested that in the pres-
ence of SIV microglial cells, which are the majority of
the cell isolate, increased the expression of Iba-1 (Fig. 1e
and f, respectively) compared to controls (Fig. 1d). In
addition, the combination of Meth and SIV infection po-
tentiated the increase of Iba-1 expression (Fig. 1g), sug-
gesting that high microglial activation induced by SIV is
enhanced by Meth. The increase in Iba-1 expression was
confirmed by image analysis using ImageJ, where thre-
sholded stained particles further adjusted to eliminate
counterstaining signal, were converted into brightness
and quantified. Using this strategy Iba-1 occurred in
5.58 % of the control frontal cortex tissue (±0.06), with a
significant increase to 7.16 % (±0.18, p = 0.021, using
Bonferroni’s post hoc test) due to SIV infection. Meth-
treated animals presented 6.43 % (±0.010) of the frontal
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cortex area stained with Iba-1 antibody, which was sig-
nificant compared to controls (p = 0.029). In SIV/Meth
animals we found that 8.78 % of the frontal cortex area
was Iba-1-positive (p = 0.045 compared to SIV alone).
The increase in Iba-1 staining in SIV/Meth was accom-
panied by an increase in the frequency of perivascular
inflammatory cells as well as an increase in the size of
cells with microglia morphology, thereby shifting the in-
flammation from mild to moderate. Thus, all infected
animals exhibited signs of inflammatory response, which
was characterized as mild in SIV (increased Iba-1 ex-
pression, and presence of perivascular as well as diffuse
macrophages), and moderate in the presence of SIV plus
Meth (stronger Iba-1 expression, intensified perivascular
and submeningeal infiltrate, presence of parenchymal
macrophage foci, and occasional giant cells).
Following the characterization of these brain-derived
CD11b-rich immune cells, the isolates were processed
for gene array and differences in gene expression be-
tween groups were mapped to establish the fingerprints
of SIV and Meth abuse within the innate immune and
lymphoid populations. Following hybridization proce-
dures, the differences between groups were detectable
upon visual inspection of hybridized microarrays. Abso-
lute signal intensity ratios were estimated between
paired groups. The complete expression dataset was
then mapped, and groups were compared. Hotelling
confidence interval calculation did not identify outliners,
and comparisons were performed using both ANOVA
and a two-factor general linear model.
The significant changes in gene expression due to SIV
and/or Meth were analyzed for identification of gene sig-
natures, which were further analyzed using an integra-
tive systems biology approach described as follows. By
filtering the data to consider only genes that were up-
regulated to above 1.5-fold in group comparisons, with a
p value <0.05, the number of genes that were changed in
different conditions was as follows: Meth treatment
alone significantly up-regulated 1359 genes compared to
Controls; SIV infection increased 1948 genes in isolated
microglia compared to controls. The introduction of
Meth treatment in SIV-infected macaques induced the
up-regulation of 481 genes in comparison to SIV alone,
and of 715 genes in comparison to Meth alone. In
addition, there were 311 genes up-regulated in both
Meth alone and in SIV alone, of which 9 were also up-
regulated in SIV/Meth, and 60 have been also found in
microglia from animals exhibiting disease progression
and encephalitis encephalitis. A visual representation of
the number of upregulated genes in individual groups
can be found in Fig. 2.
Pathway assignments and functional annotations were
analyzed using DAVID Bioinformatics Database [20], As
well as Ingenuity Knowledge Base [21] and an inter-
action repository, which is based on cpath [22–24] and
includes interactions that have been curated by GeneGo
(http://portal.genego.com) and Ingenuity. Networks re-
trieved from the latter were visualized using Cytoscape
[25]. Both resources were queried using Markov cluster-
ing (MCL) algorithm, to infer how the derived differen-
tial expression data may interact with established Gc
pathways. This approach was utilized to facilitate the
visualization of Meth’s interference on molecular pat-
terns triggered by the virus. We examined a select num-
ber of pathways based on their score and relevance to
immune pathology.
The genes up-regulated by each condition in comparison
to controls were clustered for functional annotation using
DAVID Bioinformatics Database and the 15 most upregu-
lated genes in each group were highlighted (Tables 1, 2, 3,
4, and 5). In Cytoscape, pathways were scored following
the application of Markov clustering (MCL) algorithms,
and nodes were obtained according to the number of
assigned up-regulated genes using Cytoscape interface.
Pathways with four or more up-regulated genes are re-
ported. Meth significantly affected genes of the immune
system and metabolic signaling pathways, suggesting the
drug deeply modifies microglia cells.
Fig. 2 Venn diagram indicating the number of significantly upregulated genes in SIV, Meth and SIV/Meth groups, as well as SIV, Meth and SIVE
animals. Genes represented were increased above 1.5 fold with a p value≤ 0.05 in comparisons
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A1. Meth alone upregulates pathways and genes involved
in signaling and in immune functions
Meth significantly increased immune system and meta-
bolic signaling pathways (Table 1). Table 2 shows the
most up-regulated genes in Meth-treated animals in
comparison to uninfected controls. These genes have
been assigned to pathways involved in a broad number
of pathways, such as in disulfide bonds, cell surface
receptor-linked signal transduction, chemotaxis, and re-
sponses to wounding, regulation of cell proliferation, im-
mune and inflammatory responses.
A2. SIV alone upregulates pathways and genes associated
with the CNS viral response
The genes up-regulated in isolated microglial cells by
SIV alone in comparison to controls were clustered for
Table 1 Functional annotation chart for microglia gene pathways that were significantly up-regulated by Meth in microglia, as com-
pared to controls. Number of genes, p-value and Benjamini value are presented. Complete data set is presented in Additional file 1:
Table S1
Category Term Count P-value Benjamini
KEGG_PATHWAY Cytokine-cytokine receptor interaction 24 9.00E-07 1.30E-04
GOTERM_BP_FAT Immune response 18 1.90E-03 2.50E-01
GOTERM_CC_FAT Extracellular region part 15 1.60E-02 6.30E-01
GOTERM_MF_FAT Cytokine activity 14 1.80E-03 1.90E-01
GOTERM_CC_FAT Extracellular space 14 2.10E-02 4.90E-01
KEGG_PATHWAY Natural killer cell mediated cytotoxicity 13 8.10E-04 5.50E-02
KEGG_PATHWAY Chemokine signaling pathway 13 3.20E-02 2.90E-01
GOTERM_BP_FAT Defense response 12 1.40E-02 4.60E-01
KEGG_PATHWAY Jak-STAT signaling pathway 12 1.80E-02 2.00E-01
KEGG_PATHWAY T cell receptor signaling pathway 10 1.50E-02 2.10E-01
KEGG_PATHWAY Hematopoietic cell lineage 9 1.10E-02 1.80E-01
KEGG_PATHWAY Toll-like receptor signaling pathway 9 2.30E-02 2.40E-01
KEGG_PATHWAY NOD-like receptor signaling pathway 8 5.50E-03 1.40E-01
KEGG_PATHWAY Allograft rejection 8 7.40E-03 1.60E-01
GOTERM_BP_FAT Response to wounding 8 1.30E-02 5.10E-01
KEGG_PATHWAY Fc epsilon RI signaling pathway 8 1.70E-02 2.10E-01
KEGG_PATHWAY Asthma 7 2.00E-03 6.80E-02
GOTERM_BP_FAT Inflammatory response 7 7.90E-03 3.90E-01
KEGG_PATHWAY Cytosolic DNA-sensing pathway 7 8.20E-03 1.50E-01
KEGG_PATHWAY Autoimmune thyroid disease 7 5.70E-02 4.20E-01
GOTERM_BP_FAT Chemotaxis 6 1.40E-02 4.20E-01
GOTERM_MF_FAT Cytokine binding 6 3.40E-02 8.60E-01
GOTERM_BP_FAT Locomotors behavior 6 3.40E-02 7.10E-01
KEGG_PATHWAY Graft-versus-host disease 6 4.30E-02 3.60E-01
INTERPRO Immunoglobulin 6 4.50E-02 9.00E-01
KEGG_PATHWAY Type I diabetes mellitus 6 6.90E-02 4.70E-01
GOTERM_BP_FAT Behavior 6 7.90E-02 9.20E-01
GOTERM_BP_FAT Cell migration 5 1.80E-03 4.30E-01
GOTERM_BP_FAT Cell motility 5 3.30E-03 2.90E-01
INTERPRO Small chemokine, C-C group, conserved site 5 5.50E-02 8.80E-01
GOTERM_BP_FAT Leukocyte migration 4 6.40E-03 4.00E-01
INTERPRO Chemokine receptor 4 6.40E-02 8.70E-01
GOTERM_MF_FAT C-C chemokine receptor activity 4 7.20E-02 9.40E-01
GOTERM_MF_FAT C-C chemokine binding 4 7.20E-02 9.40E-01
GOTERM_MF_FAT Chemokine receptor activity 4 9.50E-02 9.40E-01
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functional annotation using DAVID Bioinformatics
Database (Table 3), and pathways were scored according
to the number of assigned up-regulated genes. Pathways
with a count of four or more up-regulated genes are re-
ported. As expected, the microglial genes that were up-
regulated by SIV in comparison to uninfected controls
were related to the viral response in the CNS, including
antigen processing/presentation and cell death (Table 3).
Table 4 shows the fifteen most up-regulated genes in
SIV-infected brain-derived microglia compared to con-
trol, which have been assigned to pathways associated to
plasma membrane (p = 0.0005, Benjamini = 0.001), im-
mune response (p = 0.0008, Benjamini = 0.008), negative
regulation of the immune process (p = 0.0003, Benjamini =
0.003), apoptosis (p = 0.0002, Benjamini = 0.004), and regu-
lation of leukocyte proliferation (p = 0.005, Benjamini =
0.03).
A3. SIV/Meth upregulates pathways and genes involved
in metabolism and immune function
We next examined the genes that were significantly up-
regulated by Meth in SIV-infected brain-derived microglia
(SIV/Meth) in comparison to SIV alone, as described
above. In SIV-infected macaques, the introduction of
Meth significantly affected genes involved in neuroactive
synapsis interaction (p = 0.002, Benjamini = 0.008).
The fifteen most up-regulated genes in SIV/Meth
microglia, compared to SIV, showed assignments to spe-
cific pathways involved in to immunoglobulin domain
(p = 0.003, Benjamini = 0.08), Toll-like receptor response
(p = 0.004, Benjamini = 0.01), alternative splicing (p =
0.007, Benjamini = 0.07), glycoproteins (p = 0.008,
Benjamini = 0.07), and receptor signaling (p = 0.009,
Benjamini = 0.06) (Table 5).
B. Microglial gene network visualization
Gene networks were visualized using Cytoscape [25],
and queried using Markov Clustering (MCL) algorithms,
to infer how the derived differential expression data may
interact with established pathway databases. This ap-
proach was utilized to facilitate the visualization of the
influence of Meth on molecular patterns triggered by
the virus. We focused on comparisons between Meth
and Control groups (Fig. 3a, b and c), to select high
score nodes, filtered for a minimum of 3 genes showing
similar behavior, such as expression above 1.5-fold in-
crease, and a p value ≤0.05. We analyzed these changes
in parallel with changes observed in SIV only compared
to controls (Fig. 3d, e, and f ) and finally selected nodes
where the combination of Meth and SIV showed en-
hanced expression of genes compared to SIV alone
(Fig. 3g, h and i) and that could have implications in in-
flammatory outcome, enhancement of brain viral load,
and progression. This analysis led to three networks with
a role in cell survival and immune functions, which were
extrinsic apoptosis (Fig. 3a, d and g), cell migration/acti-
vation (Fig. 3b, e and h), and T-cell receptor (TCR) sig-
naling (Fig. 3c, f and i).
Regarding the extrinsic apoptosis pathway, we found
that Meth significantly upregulated genes such as Fas
(CD95, 1.53 fold, p = 0.0051),Fas LG (1.95 fold, p = 0.044),
and Caspase 1 (2.07 fold, p = 0.022) compared to controls
(Fig. 3a). Also in this pathway, NOD1 (1.6-fold, p = 0.09)
and Caspase 9 (1.58-fold, p = 0.062) were substantially but
not significantly increased. Genes in this pathway, such as
Table 2 Fifteen most up regulated genes in Meth-treated macaques in comparison to controls
Gene Name Fold change P value
GQ153436 MHC Class I Mamu-B 5.43 0.0001
MAMU-DQ MHC Class II DQ variant 4.76 0.01
FOLR1 Folate receptor 1 4.76 0.044
CCL5 Chemokine C-C motif ligand 5 3.66 0.0021
GPR160 G-protein coupled receptor 160 3.32 0.006
IGFBP1 Insulin-like growth factor binding protein 1 3.21 0.0007
PTGER2 Prostaglandin E receptor 4 2.91 0.01
CXCR2 CXC chemokine receptor 2 (IL8RB) 2.77 0.009
CCL3 Macrophage Chemoatractant Protein-1 2.63 0.03
TGFBI Transforming growth factor beta-induced 2.6 0.005
IL4 Interleukin 4 2.58 0.016
ALOX5AP Arachidonate-5-lipoxygenase activating protein 2.51 0.023
IL10 Interleukin 10 2.38 0.015
INFB1 Interferon beta 1 2.35 0.025
CCR5 Chemokine C-C motif receptor 5 2.24 0.0029
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Fas, Fas LG, NOD1, Caspases 1, 9 and 4 were signifi-
cantly increased by SIV in comparison to controls
(Fig. 3d). Meth and SIV caused a significant 1.5-fold
up-regulation (p = 0.01) of Caspase 9 when compared
to SIV alone (Fig. 3g).
Apoptotic pathways that involve the upregulation of
CD95 have been previously implicated in the progres-
sion of neuroAIDS [26]. We have identified the upregu-
lation of Fas as a characteristic of active immune cells in
the brain of SIV-infected macaques [27]. In microglia,
Table 3 Functional annotation chart for the gene pathways that were significantly up-regulated by chronic SIV in microglia, as com-
pared to controls. Number of genes, p-value and Benjamini value are presented. Complete data set is provided in Additional file 2:
Table S2
Category Term Count P-value Benjamini
GOTERM_CC_FAT Intrinsic to membrane 25 1.20E-02 1.60E-01
GOTERM_CC_FAT Integral to membrane 24 1.60E-02 1.60E-01
KEGG_PATHWAY Endocytosis 20 7.80E-03 1.10E-01
SP_PIR_KEYWORDS Transmembrane 20 8.70E-02 8.70E-01
GOTERM_BP_FAT Immune Response 19 2.10E-04 2.00E-02
KEGG_PATHWAY Cell adhesion molecules (CAMs) 19 1.00E-03 2.00E-02
KEGG_PATHWAY Cytokine-cytokine receptor interaction 18 6.30E-02 4.20E-01
INTERPRO Immunoglobulin-like fold 17 2.10E-06 2.40E-04
KEGG_PATHWAY Lysosome 17 1.00E-04 5.40E-03
KEGG_PATHWAY Natural killer cell mediated cytotoxicity 17 5.30E-04 1.20E-02
KEGG_PATHWAY Antigen processing and presentation 16 1.10E-04 3.50E-03
GOTERM_CC_FAT Plasma MEMBRANE 16 2.50E-02 1.70E-01
KEGG_PATHWAY Viral myocarditis 15 1.70E-03 3.00E-02
KEGG_PATHWAY Allograft rejection 14 3.20E-05 2.60E-03
KEGG_PATHWAY Autoimmune thyroid disease 14 2.40E-04 6.40E-03
KEGG_PATHWAY Graft-versus-host disease 13 2.60E-05 4.20E-03
KEGG_PATHWAY Type I diabetes mellitus 13 1.00E-04 4.20E-03
GOTERM_BP_FAT Antigen processing and presentation 10 5.20E-05 1.40E-02
GOTERM_CC_FAT MHC protein complex 10 5.80E-05 2.50E-03
GOTERM_CC_FAT Plasma Membrane Part 10 2.20E-02 1.80E-01
KEGG_PATHWAY Colorectal cancer 10 5.80E-02 4.20E-01
KEGG_PATHWAY Cytosolic DNA-sensing pathway 9 5.30E-03 8.20E-02
KEGG_PATHWAY Fc gamma R-mediated phagocytosis 9 9.80E-02 5.50E-01
KEGG_PATHWAY Acute myeloid leukemia 8 2.50E-02 2.70E-01
KEGG_PATHWAY Amyotrophic lateral sclerosis (ALS) 8 4.80E-02 3.90E-01
KEGG_PATHWAY Intestinal immune network for IgA production 8 4.80E-02 3.90E-01
GOTERM_CC_FAT MHC class I protein complex 7 5.80E-04 1.20E-02
SP_PIR_KEYWORDS Immune response 7 1.40E-03 6.20E-02
INTERPRO Immunoglobulin subtype 7 1.00E-02 1.40E-01
KEGG_PATHWAY Amino sugar and nucleotide sugar metabolism 7 2.40E-02 2.80E-01
GOTERM_BP_FAT Antigen processing and presentation of peptide antigen via mhc class i 6 7.00E-05 9.80E-03
INTERPRO MHC class I-like antigen recognition 6 7.90E-03 1.20E-01
KEGG_PATHWAY Primary immunodeficiency 6 3.90E-02 3.70E-01
KEGG_PATHWAY Sphingolipid metabolism 6 5.50E-02 4.20E-01
GOTERM_BP_FAT Cell death 5 2.60E-02 8.40E-01
KEGG_PATHWAY RNA polymerase 5 4.50E-02 3.90E-01
GOTERM_BP_FAT Apoptosis 4 9.50E-02 9.90E-01
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the upregulation of Fas correlates with activation after
infection, as a response to local increases in TNFα and
IFNγ [28]. Our results indicate that in both Meth-
treated and SIV-infected brain isolates, this pathway af-
fects Caspase 1 levels. SIV alone increases transcription
of Caspases 4 and 9. However, the combination of SIV
and Meth enhances the transcription of Caspase 9 com-
pared to SIV alone, which is within the non-canonical
Caspase 8-dependent pathway [29, 30]. While Caspase 1
(along with Caspase 4) is a key mediator of inflammation
[31, 32], Caspase 8 and 9 may commit cells to apoptosis
[33–35]. Suggesting that in animals infected with SIV
and treated with Meth inflammation can be accompan-
ied by loss of glial cells. Indeed, pathological analyses of
HIV-1-infected brains have shown that apoptosis is ob-
served both in neurons and in microglia [36, 37] and that
chronic Meth enhances this process [26].
We also examined a pathway that is downstream of T
cell receptor-mediated activation of T cells, which is cen-
tered in the expression of Zap70 tyrosine kinase [38].
This pathway seemed relevant, not only for a high score
upon pathway analyses, but also because CD8 T cells
can be found in the microglial fraction isolated from
brain [27], and are increased by SIV infection (Fig. 1b).
Table 4 Fifteen most up regulated genes in isolated microglia from SIV-infected macaques in comparison to controls
Gene Name Fold change P value
FCN1 Ficolin (collagen/fibrinogen domain containing) 1 20.26 0.01837
APOBEC3A Apolipoprotein B mRNA editing enzyme catalytic polypeptide-like 3A 15.34 0.04385
GZMA Granzyme A 14.96 0.04000
MAMU-A MHC class I antigen 10.64 0.00076
GZMB Granzyme B 10.02 0.00454
LPAR5 lysophosphatidic acid receptor 5 9.63 0.04561
NKG7 Natural killer cell group 7 sequence 9.11 0.02109
PDCD1LG2 Programmed cell death 1 ligand 2 9.11 0.02552
GPR18 G protein-coupled receptor 18 8.09 0.01031
LFA2 Lymphocyte function-associated antigen 2 7.74 0.00447
TIGIT T cell immunoreceptor with Ig and ITIM domains 7.53 0.04879
CHRNA1 Cholinergic receptor, nicotinic, alpha 1 7.28 0.04968
CLEC2D C-type lectin domain family 2, member D 7.01 0.03784
GLIPR1 GLI pathogenesis-related 1 6.54 0.03590
BTLA B- and T-lymphocyte attenuator-like 6.32 0.00352
Table 5 Fifteen most up regulated genes in SIV/Meth macaques in comparison to SIV
Gene Name Fold change P value
AQP9 Aquaporin 9 94.2 0.028
OAS1 2′,5′-oligoadenylate synthetase 1 11.98 0.00005
MAMU-A1 Macaca mulatta Mamu-A MHC class I antigen 5.19 0.038
GPD1 Glycerol-3-phosphate dehydrogenase 1 3.69 0.037
SERPINA1 Serpin peptidase inhibitor, clade A 3.37 0.002
VSIG1 V-set and immunoglobulin domain containing 1 3.1 0.02
NAT2 N-acetyltransferase 2 (arylamine N-acetyltransferase) 2.96 0.026
CD244 Natural killer cell receptor 2B4 2.78 0.031
IRF5 Interferon regulatory factor 5 2.66 0.032
TXNDC2 Thioredoxin domain-containing protein 2-like 2.59 0.028
IL1RAPL1 Interleukin 1 receptor accessory protein-like 1 2.29 0.007
GRIN2B Glutamate receptor, ionotropic, N-methyl D-aspartate 2B 2.29 0.003
ZSCAN1 Zinc finger and SCAN domain containing 1 2.17 0.023
GPR17 G protein-coupled receptor 17, transcript variant 2 2.13 0.016
HIVEP3 Human immunodeficiency virus type I enhancer binding protein 3 94.21 0.028
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Although the numbers of CD4+ T cells and especially of
CD8+ T cells are not affected by Meth, changes in this
pathway suggest that Meth did affect T cell activation
and response (Fig. 3b). For instance, Meth substantially
decreased the expression of a central component in TCR
signaling, Zap 70 (0.5-fold, p = 0.08), in correlation with
the significant upregulation of SLA (Src-like adaptor)
(1.8-fold, p = 0.011), which negatively regulates TCR sig-
naling [39]. LCP2 (Lymphocyte cytosolic protein 2)(2.1-
fold, p = 0.008), SH3BP2 (SH3-domain binding protein
2)(1.93-fold, p = 0.05), and CD2 (LFA2)(12.85-fold, p =
0.045) were also significantly upregulated by Meth. As
expected, this pathway was highly upregulated by SIV
infection in comparison to controls (Fig. 3e). In addition,
the combination of Meth and SIV substantially enhanced
the expression of components of this node (Fig. 3h).
The ability of both Meth and SIV alone to upregulate
the substrate of Zap70 protein, LCP2 (Lymphocyte cyto-
solic protein 2), the cooperating molecule SH3BP2
(SH3-domain binding protein 2), and the early T cell dif-
ferentiation marker CD2, could be due to changes in the
absolute numbers of CD8 T cells. However, neither SIV
Fig. 3 Highest scoring significant modules associated to immune functions in microglia from Meth-treated macaques. Comparisons between
Meth and controls (a, b, c), SIV and controls (d, e, f), and SIV/Meth and SIV (g, h, i) were performed using Cytoscape interface, and Biogrid plugin.
Data was filtered based on fold-change above 1.5-fold and p value <0.05. Clustered gene nodes were selected to present at least two upregulated
genes in Meth compared to controls, and to have a described role affecting CNS immune functions and viral load. These filtered nodes were related
to extrinsic apoptotic pathways (a, d, g), T-cell receptor (TCR) signaling (b, e, h), and macrophage and microglia activation and chemotaxis (c, f, i). Red
color intensity signifies upregulation levels, and green signifies down-regulation. Shapes indicate significance, being squares p < 0.05 and circles >0.05
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nor Meth was able to significantly change the expression
of Zap70. Meth alone increased the expression of the
Zap70-cooperating molecule SLA (Src-like adaptor),
suggesting an effect on the adaptative branch of the im-
mune response. SIV alone triggered the expression of
CD3ε, Syk and TUBA1B (Tubulin alpha), suggesting
TCR mediated antigen recognition, activation, and cyto-
skeleton organization [40]. Importantly, the combination
of Meth and SIV did not enhance this T cell receptor-
mediated pathway compared to SIV alone. Thus con-
firming that the major additive and synergistic effects of
Meth and SIV occur in innate immune cells of the brain.
Meth also upregulated pathways involved in chemo-
taxis of immune cells as well as microglial motility. For
instance, Meth increased the expression of CCR5 by
2.24-fold (p = 0.01) and CXCR4 by 2.29-fold (p = 0.01)
(Fig. 3b). This data is in accordance with previous obser-
vations suggesting that Meth increases the availability of
virus target cells. These same genes were upregulated by
SIV, in addition to IFNGR1, when compared to controls
(Fig. 3e). In SIV/Meth microglia, the upregulation of
CCR5 and CXCR4 did not differ in comparison to SIV.
However, the expression of another gene in this path-
way, SOCS1 (Suppressor of cytokine signaling 1), a
marker of DNA damage and senescence [41], was sig-
nificantly increased in SIV/Meth microglia (1.73-fold, p
= 0.05). Within the same pathway, Meth in SIV-infected
brain isolates substantially upregulated the expression of
IL2RG (6.7-fold, p = 0.26) (Fig. 2i).
C. Increased expression of inflammatory and viral target
molecules in Meth microglia
The identification of cell migration pathways in associ-
ation with Meth exposure raised a special interest, not
only from the inflammatory perspective, but also from
the fact that the surface molecules that facilitate the
entry of the SIV and HIV viruses into host cells (CXCR4
and CCR5) were found to be highly upregulated by Meth
in our gene arrays. This finding is in accordance with
our previous study, which suggested that CCR5 upregu-
lation is a marker of disease severity associated with
Meth use in the CNS of SIV-infected macaques [19].
The in-depth examination of this pathway could lead to
the understanding of mechanisms by which Meth aggra-
vates CNS infection and outcome. Thus, we examined
genes associated with Meth-induced CCR5 upregulation
in microglia by tracking other molecular components as-
sociated with CCR5 upregulation by Meth. Importantly,
the combination of SIV and Meth caused the upregula-
tion of SOCS1 (Suppressor of cytokine signaling 1).
SOCS1 can directly inhibit the JAK kinase activation
loop and signaling through interferon (IFN) receptors
[42], which may contribute to the development of an im-
mune suppression state. Interestingly, the expression of
SOCS1 is directly correlated to the development of im-
mune senescence [41]. In parallel, CCR1 and RANTES
were also drastically elevated in animals where Meth
and SIV were combined.
Thus, given the relevance for HIV CNS pathology and
target availability, we focused on the pathways in con-
nection with CCR5 upregulation by Meth. We searched
for differences in gene expression of transcription factors
that have binding sites within the CCR5 promoter in
microglial from Meth and Control animals. We detected
a cluster showing a 2.8-fold increase (p = 0.06) in p65
(RelA), a the NF-kappaB/Rel family member, that is a
potent activator of the CCR5 promoters Pu and Pd [43]
(Fig. 4a). This was accompanied by an up-regulation of
NFKBIB (1.83-fold, p = 0.035), a NFKB deactivator that
traps NF-kappa-B in the cytoplasm [44, 45] (Fig. 4a).
In order to identify genes in the data set connected to
CCR5, that were also increased by Meth, we ran a node
search that was centered on CCR5, contained first/sec-
ond neighboring genes, that was filtered to expression
levels increased above a 1.5-fold difference in Meth
compared to control microglia (Fig. 4b). Using this ap-
proach we identified a large node showing the increase
of the CCR5 ligand, CCL5/RANTES (3.7-fold, p =
0.0008) (Fig. 4b, Table 6) and other genes that exhibit
pro-inflammatory properties (Table 6). This network, in-
cluding second neighbors, was predominantly annotated
to chemotaxis, calcium homeostasis, and inflammatory
response (p < 0.0001, Benjamini < 0.0001). Other CCR5-
related genes that can be important in pathogenesis
included IL16, which can also bind to and attract CCR5-
expressing cells [46], and Stat6, a marker of M2 pheno-
type in microglia [47].
The upregulation of CCR5 and its neighboring genes by
Meth is in agreement with our previous findings [19, 48],
and provides associated molecules that may support viral
targets in Meth abuse. Therefore, we have selected CCR5
and its co-regulators, as well as other markers annotated
to inflammatory cell migration, to validate the implemen-
tation of our strategy, towards identifying relevant path-
ways from large sets of genes in SIV and Meth co-
morbidities in vivo.
The expression of genes with a role in inflammatory
cell migration in the CCR5 network was validated via
qRT-PCR using samples from brain-derived microglia
(Fig. 5). The genes tested were CCR1, CCR5, CXCR4,
CCL2 (MCP-1), CCL3 (MIP-1a), and CCL5 (RANTES).
Of these molecules, only CCR5 was confirmed by qRT-
PCR to be significantly increased by Meth in comparison
to control brain-derived microglia cells (Fig. 5b). How-
ever, the expression of the other genes examined was
substantially enhanced by Meth, both in controls and in
SIV-infected brain isolates. CCL5 (RANTES), in particu-
lar, was significantly enhanced by Meth in SIV-infected
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cells (Fig. 5f ). Overall, this suggests that Meth en-
hances microglial activation and the expression of pro-
inflammatory factors, especially those associated with sus-
ceptibility to viral infection. The correlation between CCR5
and susceptibility to HIV infection in Meth abuse has been
attributed to the elevation of dopamine levels [49].
An in depth analysis of the pathway leading to an in-
crease in CCR5-positive virus target cells in the brain [26]
revealed additional, connected, cell migration pathways.
The quest for neighboring CCR5 genes that were upregu-
lated by Meth alone, led to a network of components as-
sociated to inflammatory cell migration and development
of pro-inflammatory conditions. Of these, chemokines
and chemokine receptors were validated, confirming the
ability of Meth to favor the development of inflammatory
pathologies and increasing the availability of virus target
cells. The increase of CCR5 and its distribution in brain
frontal lobe tissue were examined via immunohistochem-
istry. In controls we found that CCR5 is expressed by few
cells exhibiting myelomonocytic morphology (Fig. 6a),
while Meth-treatment increased the intensity and number
of CCR5-positive cells perivascularly and at the paren-
chyma (Fig. 6b). As expected, SIV infection also increased
the number of cells that are highly positive to CCR5
(Fig. 6c). In addition, Meth and SIV had an additive effect
regarding the expression of CCR5-positive cells (Fig. 6d),
including multinucleated giant cells (Fig. 6e), suggesting
that moderate encephalitis occurred in correlation with
increased brain viral load in those animals (Fig. 6f). The
increase in CCR5 expression was confirmed by image ana-
lysis, using Image J. The measurements of CCR5-positive
staining intensity, converted into percentage of the total
area, revealed a significant increase in CCR5 tissue expres-
sion induced both by Meth alone (2.48 % ± 1.16) and by
SIV alone (3.15 % ± 0.87), when compared to controls
(0.91 % ± 0.35), with p values = 0.01 and 3.73E-05, respect-
ively. SIV/Meth showed the increased effect of interaction
(5.72 % ± 2.11), and CCR5 staining was significantly higher
in that group, when compared to Meth alone (p = 0.0047)
and to SIV alone (p = 0.0025).
Fig. 4 Genes changed by Meth in connection with CCR5 in rhesus monkey’s brain-derived immune cells. a Network containing transcription factors
that have binding sites in the CCR5 promoter. b CCR5 centered network filtered for genes with expression above 1.5-fold. Circles indicate p > 0.05 and
squares indicate p < 0.05
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Interestingly, the increase of viral load in the brain of
Meth-treated SIV-infected animals compared to SIV did
not correlate with viral levels in the plasma, or CSF (not
shown), confirming a previous report [19]. This observa-
tion is in support of studies suggesting that viral load in
brain parenchyma correlates with the development of
overt neurological functions, when compared to plasma
[50]. However, it has been suggested that viral antigen con-
tributed by viral production within the brain, not absolute
amount of viral load in the CSF, correlates more accurately
with the development of neurological disease [50]. There-
fore, the levels of virus in the brain parenchyma may pre-
cede the elevation of CSF viral load. Alternatively, because
viral load was measured in cell-free CSF samples, differ-
ences in CSF viral load between SIV and SIV/Meth could
be due to changes in the number of infected cells rather
than free circulating RNA. Another explanation for a higher
viral load in the brain, but not in the CSF, of Meth-treated
animals could be potential disruptions in bi-directional
flow and diffusion to intra-ventricular spaces.
Remarkably, the high viral load in the brain paren-
chyma associated to the finding that Meth abuse in-
creases CCR5 expression has implications to the
understanding of the epidemiology of HIV spread. Meth
abusers, are not only more often at risk to become ex-
posed to HIV, but also are immediately more susceptible
to acquire infection and drive the virus towards the
CNS. The ability of Meth to do this arises from its en-
hancement of pathways that lead to CCR5 upregulation
in macrophages and glial cells. This finding may explain
the high incidence of inflammatory pathologies in the
brain and elsewhere among Meth abusers [51–53].
Table 6 Genes significantly changed in connection with the upregulation of CCR5 in Meth compared to control microglia
CanonicalName Meth/Ctr FC Meth/Ctr pvalue Name
CCL5 3.664732509 0.0008 Chemokine (C-C motif) ligand 5
RALGPS2 2.894990056 0.0206 Ral GEF with PH domain and SH3 binding motif 2
CCL3 2.632055343 0.0160 Chemokine (C-C motif) ligand 3
IL8 2.330578386 0.0152 Interleukin 8
KIF23 2.32350165 0.0090 Kinesin family member 23
PRPF19 2.277978004 0.0486 PRP19/PSO4 pre-mRNA processing factor 19 homolog (S. cerevisiae)
CCR5 2.244743162 0.0149 Chemokine (C-C motif) receptor 5
IL16 2.22856945 0.0025 Interleukin 16 (lymphocyte chemoattractant factor)
TGFB1 2.094232364 0.0181 Transforming growth factor, beta 1
PTK2B 2.075586714 0.0239 PTK2B protein tyrosine kinase 2 beta
CXCR4 2.290261762 0.0151 Chemokine (C-X-C motif) receptor 4
CCL2 1.976229643 0.0052 Chemokine (C-C motif) ligand 2
CCR1 1.944997932 0.0463 Chemokine (C-C motif) receptor 1
FGFR2 1.803077177 0.0075 Fibroblast growth factor receptor-2
PIN1 1.76086754 0.0429 Peptidylprolyl cis/trans isomerase, NIMA-interacting 1
VDAC1 1.745554071 0.0238 Voltage-dependent anion channel 1; similar to voltage-dependent anion channel 1
SIRPA 1.655090623 0.0180 Signal-regulatory protein alpha
PTPN6 1.651490977 0.0182 Protein tyrosine phosphatase, non-receptor type 6
AP2A1 1.648603535 0.0347 Adaptor-related protein complex 2, alpha 1 subunit
CRTC2 1.612923593 0.0216 CREB regulated transcription coactivator 2
ITGB5 1.580576538 0.0274 Integrin, beta 5
AR 1.575448506 0.0400 Androgen receptor
TNFAIP3 1.563086606 0.0044 Tumor necrosis factor, alpha-induced protein 3
BTRC 1.552901893 0.0263 Beta-transducin repeat containing
C5orf25 1.542952379 0.0097 Chromosome 5 open reading frame 25
NAGPA 1.524456014 0.0027 N-acetylglucosamine-1-phosphodiester alpha-N-acetylglucosaminidase
SDC4 1.523650476 0.0487 Syndecan 4
STAT6 1.482833897 0.0044 Signal transducer and activator of transcription 6
A network that includes significantly upregulated first and second neighbors of CCR5, which appears in bold, was generated. Values represent fold change in
Meth versus Control microglia and p value
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D. The combination of Meth and SIV increases the
expression of genes associated to encephalitis and
disease progression
We were interested in identifying genes whose SIV-
induced expression was potentiated by Meth, which
could be predictive of an encephalitic outcome and
could have a translational potential. In order to find
genes with a severity predictive value, we compared the
gene expression in brain cell isolates from Meth, SIV,
and SIV/Meth microglia with previously characterized
samples from SIV infected animals that had a severe en-
cephalitis associated with fast disease progression (SIVE)
[54]. The SIVE group differs from the SIV group in that
it presents severe inflammatory pathology with strong
diffuse and large focal inflammatory aggregates, which
are not restricted to the perivascular domain, as well as
multinucleated giant cells. The encephalitis in the SIVE
group of animals developed spontaneously, as opposed
to other models in which encephalitis is induced by CD8
depletion [55]. With such a comparison, we aimed at
finding genes with expression levels potentiated by Meth
and SIV to levels that were similar to what was observed
in severe SIV inflammatory pathology.
The SIV-infected macaques that were treated with
Meth developed mild to moderate encephalitis, with
some perivascular infiltrate, eventual multinucleated
giant cells, and microgliosis (Fig. 5), but did not exhibit
the severe macrophage migration and parenchymal in-
flammatory foci typical of SIVE. They also presented an
increase in five genes highly elevated in severe SIV cases
of spontaneous encephalitis (Fig. 6). These genes were
CXCR3 (IP10), IL2RG (IL2R common gamma chain),
PYCARD (Apoptosis-associated speck-like protein
containing a CARD), IL10, and LGALS9 (Galectin 9)
(Fig. 7). This suggests that Meth and SIV, as co-
morbidities, can increase levels of molecules associated
with severity of CNS inflammation. Further proposing
that Meth can induce changes in the CNS immune en-
vironment that increase predisposition to a severe in-
flammatory outcome. Of the genes that were commonly
upregulated in SIVE and SIV/Meth, we have validated
and confirmed the enhanced expression of CXCR3 (IP10
receptor), IL2RG (IL2 receptor common gamma chain),
PYCARD, IL10 and LGALS9 (Galectin-9). These genes
were significantly increased in SIV/Meth animals, com-
pared to SIV only controls, in a similar fashion to the
SIVE group. Individually, the identified genes have been
described in correlation with brain inflammation. For in-
stance, the transcriptional increase of IP10 and CXCR3
is common to several CNS inflammatory pathologies, in-
cluding HIV [56, 57]. In addition, blocking CXCR3 re-
duces HIV-1 replication in vitro [57]. IL2RG is an
important signaling component of many interleukin re-
ceptors, including IL15, which we have shown to be up-
regulated in the brain of SIV-infected macaques in
correlation with homeostatic proliferation and persist-
ence of pathogenic CD8 T cells [58]. Interestingly, over-
expression of IL2RG has been linked to schizophrenia
[59], which is one of the potential outcomes of mental
dysfunction in association with HIV [60–62]. PYCARD
is one of the components of the inflammasome, which is
potentially activated by TLR-mediated viral recognition
signaling pathways that enhance the inflammatory envir-
onment in the CNS [63–65]. Although IL10 is described
as an immune-modulator, it has been shown to be a
marker of HIV brain disease [66]. Finally, LGAL9 is a
Fig. 5 Effect of Meth and SIV on the expression levels of CCR5 and its associated chemokine and chemokine receptor genes in microglia. The
expression of a CCR1, b CCR5, c CXCR4, d CCL2, e CCL3 and f CCL5 were measured using qRT-PCR. Expression levels were normalized to the ex-
pression of GAPDH. Values represent the average ± SEM. N = 4 animals/group. *p≤ 0.05 in comparisons shown in lines (One-way ANOVA, followed
by Bonferroni’s post-hoc test)
Najera et al. BMC Immunology  (2016) 17:7 Page 13 of 19
glycoprotein that is expressed in the brain by several in-
nate immune cells [67, 68], and that can potentiate the
infection in CD4 T cells that express a protein disulfide
isomerase (PDI) ligand [69]. On the other hand, LGAL9
binding to another T cell ligand, T-cell immunoglobulin
mucin domain 3 (Tim-3), can make cells more resistant
to HIV infection by down-regulating co-receptors of
viral entry [70]. However, in other models, the expres-
sion of LGAL9 is associated with apoptosis and a de-
creased capacity of T cells to perform immunity
functions, in a Tim-3 dependent way [67, 68]. The role
of this molecule in the brain, in the context of HIV is
not clear. Nevertheless, the increase of its levels in
microglia from both SIVE and SIV/Meth samples
suggests that this molecule can be a marker of dysfunc-
tional inflammatory pathways. Whether these genes are
early markers of inflammatory severity remains to be
examined.
Microglial cells are critical regulators of brain health
and show pro-inflammatory phenotypes that may be det-
rimental to neuronal health. Activation of microglia and
inflammation are associated to several neuropathologies,
affecting neuronal behavior and survival while respond-
ing to local and systemic insults [71]. Isolation of micro-
glia from the brain of SIV/Meth macaques allowed a
clean evaluation of the changes in microglia that are as-
sociated with the aggravation of SIV-induced CNS dis-
ease caused by Meth exposure, which may reveal
Fig. 6 Detection of CCR5 and virus on brain tissue. CCR5 expression was analyzed using Immunohistochemistry on the layer III of frontal cortex
from macaques that were a Uninfected and untreated controls, b Meth-only treated, c SIV-only infected, and d SIV-infected and Meth-treated.
e SIV-infected and Meth-treated. Pictures were at 16× magnification. Sites of interest (rectangles) were further magnified. f Brain viral load (Student’s t test)
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parallels with the analogous human condition. In fact,
persistently activated microglia have been described in
Meth users, even during periods of abstinence [18].
Microglial activation is in strong association with poor
executive functioning [72] and the combination of Meth
and HIV results in a worsening of cognitive functions
[73]. The faster decay of CNS functions may partially re-
sult from poor adherence to anti-retroviral treatments
[74]. However, it may also arise from the effects of the
drug on the innate immune environment in the CNS,
which may contribute to an elevated viral load, as ob-
served by us in the SIV macaque model [19].
Our characterization of Meth induced transcriptional
changes in microglia isolated from SIV-infected samples
confirms the role of Meth abuse in promoting a pro-
inflammatory environment in the brain. Meth treated
samples featured an elevation of several molecules that
facilitate the accumulation of inflammatory cells and
phenotypic activation. For instance, genes in pathways of
apoptosis, cell migration, and activation of T cells have
been identified.
We found that hallmarks that distinguish relevant
pathways of inflammation triggered by chronic Meth use
were highlighted by an approach of isolation of immune
cells from the brain. In addition, we confirmed the cap-
acity of Meth to enhance CCR5-expressing targets cells
for SIV in the brain. This finding potentially explains
why increased viral load and neurotoxicity is found in
SIV/Meth macaques and humans infected with HIV that
consume Meth [26]. Collectively, the results suggest that
changes caused by Meth in microglial cells play a
significant role in the outcome of CNS disorders in the
context of HIV infection.
Conclusions
– Signals from particular groups of cells may be
diluted in genomic analysis performed in whole
brain tissue. The isolation of microglial cells to study
changes in the gene expression profile that are
caused by Meth, in the context of neuroAIDS,
allowed a better analytical resolution to understand
the effects of the drug on non-neuronal innate im-
mune cell populations, and a focus on immuno-
logical parameters affecting the CNS environment,
and in particular, interfering with susceptibility to in-
fection and with CNS disease outcome towards SIV
or HIV infection.
– Meth is one of the largest health problems
associated to HIV exposure, and as a co-morbidity,
increases CNS viral load in infected individuals. The
examination of the effects of chronic Meth exposure
in rhesus macaques showed that the drug altered
the gene expression profile of CNS microglia cells
and of brain-infiltrating immune cells, by promoting
apoptotic and pro-inflammatory pathways, especially
characterized by the enhancement of genes associ-
ated to chemokines and chemokine receptors.
Within this pathway, the expression of CCR5 and its
associated genes was largely relevant, due to the im-
plications of this molecule in the susceptibility to
SIV, which, like HIV, utilizes CCR5 as a co-receptor
for entry into host’s cells in the brain. Therefore, the
upregulation of CCR5 in Meth-exposed individuals
increases the availability of virus targets, which may
contribute to the higher viral load observed in the
brain of SIV-infected, Meth-exposed animals, and of
HIV-infected individuals.
– Meth treatment triggered the high expression of
inflammatory markers that are also associated to
rapid disease progression and cognitive decay,
among them CXCR3, IL2RG, PYCARD, IL10 and
LGALS9. This suggests that the drug induces
potential pre-requirements associated to
progression.
Methods
Monkeys and SIV infection
SIV-, simian retrovirus type D-, and herpes B virus-free
rhesus macaques of Chinese origin purchased from Valley
Biosystems (West Sacramento, CA) were infected with a
cell-free SIV stock derived from SIVmac251 [75, 76]. All
experiments had the approval from the Scripps Research
Institute Animal Care and Use Committee and followed
National Institutes of Health guidelines. Animals kept in
Fig. 7 Gene expression of inflammatory molecules upregulated by
both Meth and SIV co-morbidities that are also elevated in SIVE. These
genes were selected based on the statistical significance observed in
all groups compared to controls, between Meth or SIV individually and
Meth/SIV as co-morbidities, but that were not different between SIV/
Meth and SIVE, in gene array. *p≤ 0.05 in comparisons shown in lines
(One-way ANOVA, followed by Bonferroni’s post-hoc test)
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containment were anesthetized with 10 to 15 mg/kg of
ketamine intramuscularly before procedures. At necropsy,
performed after terminal anesthesia, animals were intra-
cardially perfused with sterile PBS containing 1 U/ml hep-
arin. Brain tissue samples were taken for cell isolation,
virus quantification, and formalin fixation for histology.
Viral quantification
Brain SIV RNA was calculated by using a quantitative
branched DNA signal amplification assay, performed by
Siemens Clinical Laboratory (Emeryville, CA).
Meth treatment
Meth was administered by intramuscular injection as pre-
viously described [77]. Briefly, Meth treatment was initi-
ated at 19 weeks p.i. in animals with a stable plasma viral
load. Escalating protocol was designed to mimic Meth
abuse conditions, by administering the drug 5 days a
week, twice a day, and further increasing the dose to reach
a final dose of 2.5 mg/kg twice daily, after a 5-week ramp-
up, for a total of 25 mg/kg/week [55, 77]. This level was
then maintained for an additional 18 weeks. Three ani-
mals received PBS injections on the same schedule. All
animals were sacrificed at 42 weeks p.i.
Microglial cell isolation
The brain tissue was removed at necropsy after intravas-
cular perfusion. For isolation of cells from the brain, the
brain was carefully freed of meninges. Brain immune cells
were isolated from all areas of the brain, by enzymatic di-
gestion of minced tissue, followed by Percoll (Sigma-Al-
drich) gradient, as described previously [27]. The isolated
cells were quantified in a Z2 Coulter Counter (Beckman
Coulter, Brea, CA), and further characterized by flow cy-
tometry, using anti-CD11b (clone M1/70, BD Pharmin-
gen, San Diego, CA), anti-CD45LCA (clone 2B11, BD
Biosciences, San Diego, CA), anti-CD14-PE (clone M5E2,
BD Pharmingen, San Diego, CA), anti-CD16-FITC (clone
3G8, BD Pharmingen), anti-monkey CD3-biotin (clone
FN-18, Invitrogen Biosource, Carlsbad, CA) followed by
streptavidin-PerCP or -APC (BD Pharmingen), anti-
human CD8-PE, −FITC, or -PeCy5 (clone DK25, Dako,
Carpinteria, CA), anti-CCR5, CCR2, CX3CR1, CD80 (BD
Biosciences, San Jose, CA), and CD44v6 (clone 2 F10,
Zymed, San Francisco, CA).or isotype controls (BD Phar-
mingen). Stained cells were acquired by a FACSCalibur
(BD Biosciences, San Jose, CA) flow cytometer, and ana-
lyzed in FlowJo 6.2.1 software (Tree Star Inc., Ashland,
OR), as previously described [27].
Samples, labeling and gene array
Gene analysis was performed on cryopreserved micro-
glial cells, by custom Miltenyi Biotec Array Services. All
samples were individually performed in duplicate. RNA
was isolated from all macaques using standard RNA ex-
traction protocols (NucleoSpin RNA II, Macherey-
Nagel). Quality of the samples was checked via Agilent
2100 Bioanalyzer platform (Agilent technologies). A
RNA integrity number (RIN) was calculated by a propri-
etary algorithm that takes several QC parameters into
account, such as 28S/18S RNA peak area ratios and un-
expected peaks in the 5S RNA region, and RIN number
of 10 indicates high quality, and 1 low quality. A RIN >6
is of sufficient quality for gene expression profiling ex-
periments [78, 79]. All samples, except for 1 (animal 492
– Normal control) showed values above 6. That animal
was excluded from the analysis, leaving the healthy con-
trol group with an n = 4. For the linear T7-based amplifi-
cation step, 100 ng of each total RNA sample was used.
To produce Cy3-labeled cRNA, the RNA samples were
amplified and labeled using the Agilent Low Input Quick
Amp Labeling kit (Agilent technologies) following the
manufacturer’s protocol. Yields of cRNA and the dye in-
corporation rate were measured with the ND-1000 spec-
trophotometer (Nanodrop Technologies). The
hybridization procedure was performed according to
Agilent 60-mer 0ligo microarray processing protocol
using the Agilent gene expression hybridization kit (Agi-
lent Technologies). Briefly, 1.65ug Cy3-labeled frag-
mented cRNA in hybridization buffer was hybridized
overnight (17 h, 65oC) to Agilent Whole Rhesus monkey
Genome oligo microarrays 4×44K (one-color) using Agi-
lent’s recommended hybridization chamber and oven.
Finally, the microarrays were washed once with the Agi-
lent Gene expression wash buffer 1 for 1 min at room
temperature, followed by a second wash with pre-heated
Agilent Gene expression wash buffer 2 (37oC) for 1 min.
The last washing step was performed with acetonitrile.
Fluorescent signals of the hybridized microarrays were
detected using Agilent’s microarray Scanner System
(Agilent Technologies). The Agilent Feature extraction
software (FES) was used to read out and process the
microarray image files, determining feature intensities
(including background subtraction), rejecting outliers
and calculating statistical confidences. For determination
of differential gene expression FES derived output data
files were further analyzed using Rosetta Resolver gene
expression data analysis system (Rosetta Biosoftware),
for comparing two single intensity profiles in a ratio
experiment.
Systems analysis
Pathway assignments and functional annotations were
analyzed using DAVID Bioinformatics Database [20]. To
complete the bioinformatics analysis, two knowledge
base resources were queried: the Ingenuity Knowledge
Base [21] and an interaction repository, which is based
on cpath [22–24] and includes interactions that have
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been curated by GeneGo (http://portal.genego.com), the
Kyoto Encyclopedia of Genes and Genomes (KEGG -
http://www.genome.jp/kegg/), and Ingenuity. Benjamini
False Discovery Rate (FDR) adjusted values <0.01 and
p values < 0.05 (provided by DAVID) were utilized as
conservative filters for identification of true values.
Cluster analysis and networks were obtained and visu-
alized using Cytoscape [25].
Quantitative RT-PCR
First Strand kit (Qiagen) was used for cDNA synthesis.
Primers were designed based on available sequences for
Macaca mulatta in Gene Database for detection of rela-
tive levels using SyBrGreen/ROX in an ABI HT7900 ma-
chine. Data was analyzed with Sequence Detection
System software and expressed in relative values follow-
ing the normalization with GAPDH expression.
Immunohistochemistry
Following perfusion, the brain tissue was fixed in 10 %
buffered formalin for 48 h, followed by 70 % ethanol.
Tissues were embedded in paraffin, cut into 5 μm sec-
tions, and mounted on glass slides. Rehydrated sections
were blocked to endogenous peroxidase activity by treat-
ing slides with 3 % hydrogen peroxide in absolute
methanol. Following that, the slides were placed in a so-
lution of 0.01 M Citrate, pH 6.39, in a humidified heated
chamber, for antigen exposure. Sections were blocked
with 5 g/l Casein (Sigma Aldrich) in PBS, containing
0.5 g/l Thimerosal (Sigma Aldrich) and incubated with
Iba-1 (Wako Lab Chemicals, Richmond, VA) or the anti-
human CCR5 (NBP2-31374, Novus Biologicals, Littleton,
CO), each one diluted in Casein buffer. Biotinylated goat
anti-rabbit IgG antibodies (Vector Labs, Burlingame,
CA) were used at a 1/300 dilution. Visualization was
achieved using biotin/avidin-peroxidase (Vector Labs)
and Nova Red (Vector Labs). Counterstaining was made
with Gill’s hematoxylin. Images were captured using an
Axiovert 200 inverted microscope (Carl Zeiss) with Axio
Vision software (version 4.8.1; Carl Zeiss). Image analysis
was performed in Image J 6.4 (NIH, USA). For that, tiff
image files were opened and manually thresholded to
identify stained cells. A binary mask was obtained from
the negative thresholded image and measurement values
were calculated as percentage of the total area. This was
performed in a minimum of 5 fields per section, and two
sections per animal.
Statistics
Group comparisons were performed using the tests de-
scribed in the text and figure legends. The difference be-
tween the means was considered significant at P < 0.05.
Tests were performed using Excel (Microsoft Corporation,
Redmond, WA) and Prism software (GraphPad Software
Inc., San Diego, CA) for Macintosh.
Ethics approval and consent to participate
All experiments had the approval from the Scripps
Research Institute Animal Care and Use Committee and
followed National Institutes of Health guidelines.
Availability of data and material
The data supporting our findings can be found in
Additional files 1, 2 and 3: Table S1, S2 and S3.
Additional files
Additional file 1: Complete list of genes upregulated in microglia
isolated from Meth-treated animals compared to controls. Genes in this
list are increased above 1.5-fold in Meth versus control, with a p value
below 0.05. (XLSX 167 kb)
Additional file 2: Complete list of genes upregulated in microglia
isolated from SIV-infected animals compared to controls. Genes in this list
are increased above 1.5-fold in SIV versus control, with a p value below 0.05.
(XLSX 306 kb)
Additional file 3: Complete list of genes upregulated in microglia
isolated from animals that are SIV-infected and Meth-treated compared
to SIV-infected animals. Genes in this list are increased above 1.5-fold in
MethSIV versus SIV, with a p value below 0.05. (XLSX 69 kb)
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